Charles River Laboratories Intl. Inc vs Crowdstrike Holdings Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while Crowdstrike Holdings Inc trades at $275.04 (market cap $269.31B). The key difference: Crowdstrike Holdings Inc is far larger — about 18.9× Charles River Laboratories Intl. Inc's market cap, and Crowdstrike Holdings Inc is more actively traded (9,381,560 versus 1,176,885). Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Crowdstrike Holdings Inc for 97 Days on average.
| CRL | CRWD | |
|---|---|---|
Market Cap | $14.23B | $269.31B |
Volume | 1,176,885 | 9,381,560 |
Sector | Health | Technology |
52-Week High | $310.77 | $278.86 |
52-Week Low | $149.93 | $87.56 |
Typical Hold Time | 33 Days | 97 Days |
Enterprise Value | $17.06B | $265.11B |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298, down 0.77% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus price target. The stock maintains a bullish technical outlook with support at $292 and resistance at $301, while recent earnings have consistently beaten expectations despite negative net income margins. The company's 2026 Investor Day highlighted a strategic vision targeting 5-7% organic growth and $300 million in savings by 2030.
CRL presents a compelling growth story with solid operational cash flow and strategic initiatives, though investors face risks from negative profitability metrics and elevated valuation multiples. The stock's current position near analyst targets suggests limited upside without improved earnings execution, while ongoing margin pressures and debt levels require careful monitoring amid the company's transformation efforts.
CrowdStrike (CRWD) trades at $263.01, down 0.92% today but near its 52-week high. The stock shows strong technical momentum with bullish moving averages and recent earnings beats. Revenue growth remains robust at $3.95B for 2025, though profitability is challenged with a net margin of -0.49%. Analyst sentiment is overwhelmingly positive with 76% buy ratings and a $239.38 consensus target, while recent news highlights AI-driven cybersecurity demand as a key growth catalyst.
Outlook remains favorable given CrowdStrike's leadership in AI-native cybersecurity and expanding market opportunities. However, elevated valuation multiples (P/S 49.86) and competitive pressures present risks. The stock's proximity to all-time highs suggests near-term consolidation potential, but long-term growth prospects in cybersecurity remain compelling.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →CrowdStrike Holdings provides cybersecurity products and services aimed at protecting organizations from cyberthreats. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, identity protection, and log management. CrowdStrike went public in 2019 and serves customers worldwide.
Read more on CRWD →